-
公开(公告)号：US12161692B2
公开(公告)日：2024-12-10
申请号：US17516601
申请日：2021-11-01
Inventor： Jaume Pons , Jonathan S. Wall
Abstract: The present invention relates to SAP-Fc fusion proteins comprising one or more amino acid substitution, for example, C226S and/or C229S. In some aspects, the fusion protein comprises a structure represented by the following formula, from N-terminus to C-terminus, SAP-Fc1-L1-Fc2, wherein Fc1 is a first Fc domain sequence comprising hinge-CH2-CH3, L1 is a linker, and Fc2 is a second Fc domain sequence comprising hinge-CH2-CH3. The present invention also relates to methods of treating amyloid related diseases by administering said SAP-Fc fusion proteins to a subject in need thereof.
-
公开(公告)号：US11293925B2
公开(公告)日：2022-04-05
申请号：US16165737
申请日：2018-10-19
Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventor： Jonathan S. Wall , Emily Martin
IPC: G01N33/574 , G01N33/88 , G01N33/50 , G01N33/533 , G01N33/534 , G01N33/536 , G01N33/58 , G01N33/68
Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.
-
公开(公告)号：US09683017B2
公开(公告)日：2017-06-20
申请号：US14801717
申请日：2015-07-16
Applicant: University of Tennessee Research Foundation
Inventor： Jonathan S. Wall , Timothy E. Sparer , Stephen J. Kennel
IPC: A61K38/16 , C07K7/08 , C07K14/00 , C07K14/035 , C07K14/045
CPC classification number: C07K7/08 , A61K38/16 , C07K14/001 , C07K14/035 , C07K14/045
Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
-
公开(公告)号：US20160016999A1
公开(公告)日：2016-01-21
申请号：US14801717
申请日：2015-07-16
Applicant: University of Tennessee Research Foundation
Inventor： Jonathan S. Wall , Timothy E. Sparer , Stephen J. Kennel
CPC classification number: C07K7/08 , A61K38/16 , C07K14/001 , C07K14/035 , C07K14/045
Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
Abstract translation: 公开了治疗和/或抑制受试者的病毒感染的方法。 所述方法包括施用治疗有效量的肝素结合肽。 本文还公开了阻断病毒与细胞结合的方法。 进一步公开的是用于向感染病毒的受试者施用的抗病毒组合物。 抗病毒组合物的施用抑制受试者的病毒感染。
-
公开(公告)号：US12139529B2
公开(公告)日：2024-11-12
申请号：US18298953
申请日：2023-04-11
Inventor： Jonathan S. Wall , James S. Foster , Spencer Guthrie , Jaume Pons , Michael L. Klein
Abstract: Provided herein are antibody-peptide fusion proteins comprising an amyloid-reactive peptide linked to an antibody. Also provided herein are methods of treating amyloid-based diseases by administering an antibody-peptide fusion protein.
-
Patent Agency Ranking
公开(公告)号：US12030934B2
公开(公告)日：2024-07-09
申请号：US18181489
申请日：2023-03-09
Inventor： Jonathan S. Wall , James S. Foster , Spencer Guthrie
CPC classification number: C07K16/18 , A61K47/6843 , A61P25/28 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/01
Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
-
公开(公告)号：USRE47838E1
公开(公告)日：2020-02-04
申请号：US15883982
申请日：2018-01-30
Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventor： Jonathan S. Wall , Timothy E. Sparer , Stephen J. Kennel
IPC: A61K38/16 , C07K14/00 , C07K7/08 , C07K14/035 , C07K14/045
Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
-
公开(公告)号：US12264195B2
公开(公告)日：2025-04-01
申请号：US18660162
申请日：2024-05-09
Inventor： Jonathan S. Wall , James S. Foster , Spencer Guthrie
Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
-
公开(公告)号：US12157765B2
公开(公告)日：2024-12-03
申请号：US18660156
申请日：2024-05-09
Inventor： Jonathan S. Wall , James S. Foster , Spencer Guthrie
Abstract: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
-
公开(公告)号：US10213506B2
公开(公告)日：2019-02-26
申请号：US15504512
申请日：2015-08-24
Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Inventor： Jonathan S. Wall , Stephen J. Kennel , James S. Foster
IPC: A61K38/17 , A61P27/02 , A61K39/395 , C07K16/18 , C07K14/47 , A61K51/10 , G01N33/53 , G01N33/68 , A61K47/66 , A61K47/68 , A61K39/00
Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.017 seconds)
